Cargando…
Newer treatments for decompensated heart failure: focus on levosimendan
Acute heart failure (AHF) is a major cause of hospitalizations. Severe dyspnea, pulmonary congestion and low cardiac output with peripheral vasoconstriction and renal hypoperfusion is a main form of clinical presentation. Most patients with acute worsening have a pre-existing decompensated chronic h...
Autor principal: | Follath, Ferenc |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769227/ https://www.ncbi.nlm.nih.gov/pubmed/19920923 |
Ejemplares similares
-
Effect of β-blockade on the haemodynamic responses of levosimendan and dobutamine in the treatment of low-output heart failure
por: Follath, F, et al.
Publicado: (2002) -
Levosimendan Plus Dobutamine in Acute Decompensated Heart Failure Refractory to Dobutamine
por: Juguet, William, et al.
Publicado: (2020) -
Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers
por: Bergh, Claes-Håkan, et al.
Publicado: (2010) -
A review of levosimendan in the treatment of heart failure
por: Kasikcioglu, Hulya Akhan, et al.
Publicado: (2006) -
Levosimendan treatment for acutely decompensated heart failure is as effective for Chagas disease patients as for patients with other etiologies
por: Pereira-Barretto, AC, et al.
Publicado: (2003)